Table 7.
Comparative analysis of Healitide-GP1 with established wound-healing antimicrobial peptides from recent literature47–54.
| Peptide | Length (aa) | Net charge | MIC (µg/mL) | Cell viability | Wound closure (24 h) | Clinical stage |
|---|---|---|---|---|---|---|
| Healitide-GP1 | 25 | −2.58 | S.aureus: 12.5; E.coli: 25 | > 95% at 100 µg/mL | 48–52% | Preclinical |
| LL-37 | 37 | + 6 | Variable (16–64) | Toxic > 10 µg/mL | 35–45% | Clinical trials |
| Pexiganan (MSI-78) | 22 | + 10 | S.aureus: 12.5–25 | Cytotoxicity concerns5 | 40–45% | Phase III (failed) |
| Epi-1 | 21–25 | + 6 | MRSA: 25–50 | Non-toxic at effective doses | Complete healing in 25 days | Preclinical |
| TP3 | 23 | + 7 | Vibrio: 2.44 | Safe up to 40 µg/mL | Significant improvement | Preclinical |
| TP4 | 25 | + 10 | Similar to TP3 | Non-toxic to keratinocytes | Enhanced closure | Preclinical |
| SR-0379 | 20 | + 9 | MDR strains: effective | Low toxicity | Complete healing by day 19 | Preclinical |
| Cathelicidin-DM | 37 | + 9 | < 10 for S.a, E.c | Low cytotoxicity | Faster than control | Preclinical |
| PXL150 | Not specified | Cationic | P. aeruginosa: effective | No systemic toxicity | Improved closure | Clinical trials |
| hBD-3 | 45 | + 11 | S.aureus: 8–16; E.coli: 16–32 | Variable | 40–50% | Preclinical |